CD19 and precursor B-cell acute lymphoblastic leukemia: The characterization of the EV profile at diagnosis (D0) demonstrated that the B-ALL PB group had a decrease in platelet-derived EVs (EV-CD41a+) and an increase in endothelial cell-derived EVs (EV-CD51/61+) and B lymphoblasts/lymphocytes with CD10 and CD19 phenotype (EV-CD10+ and EV-CD19+) when compared to control group.